Combined blockade of thrombin anion binding exosite-1 and PAR4 produces synergistic antiplatelet effect in human platelets

Chin-Chung Wu; Wei-Ya Wang; Chien-Kei Wei; Che-Ming Teng

doi:10.1160/TH10-05-0305

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2011; 105(01): 88-95
DOI: 10.1160/TH10-05-0305

Platelets and Blood Cells

Schattauer GmbH

Combined blockade of thrombin anion binding exosite-1 and PAR4 produces synergistic antiplatelet effect in human platelets

Chin-Chung Wu

¹Graduate Institute of Natural Products, Kaohsiung Medical University, Kaohsiung, Taiwan

,

Wei-Ya Wang

¹Graduate Institute of Natural Products, Kaohsiung Medical University, Kaohsiung, Taiwan

,

Chien-Kei Wei

¹Graduate Institute of Natural Products, Kaohsiung Medical University, Kaohsiung, Taiwan

,

Che-Ming Teng

²Pharmacological Institute, College of Medicine, National Taiwan University, Taipei, Taiwan

› Author Affiliations

Abstract

Summary

Thrombin exosite-1 mediates the specific binding of thrombin with fibrinogen and protease-activated receptor (PAR) 1. Exosite-1 inhibitors have been shown to effectively decrease the clotting activity of thrombin, while their antiplatelet effects are relatively weak. In the present study, the inhibitory effects of two exosite-1 inhibitors, hirugen and HD1, but not the exosite-2 inhibitor HD22, on thrombin-induced platelet aggregation and P-selectin expression were dramatically enhanced by a PAR4 antagonist, YD-3. In contrast, the PAR1 antagonist SCH-79797 did not affect the antiplatelet effects of exosite-1 inhibitors. The exosite-1 inhibitors and YD-3 prevented the Ca²⁺ spike and the prolonged Ca²⁺ response in thrombin-stimulated platelets, respectively; and combination of these two classes of agents led to abolishment of Ca²⁺ signal. Unlike exosite-1 inhibitors, the antiplatelet effects of the active site inhibitor PPACK and the bivalent inhibitor bivalirudin were not significantly enhanced by YD-3. In addition, the platelet-stimulating activity of γ-thrombin, an autolytic product of α-thrombin which lacks exosite-1, was inhibited by YD-3. These results suggest that the synergistic antiplatelet effects of exosite-1 inhibitor and PAR4 antagonist are resulted from combined blockade of PAR1 and PAR4 in platelets. In fibrinogen or plasma clotting assay, YD-3 neither prolonged the clotting time on its own nor enhanced the anticoagulant activity of exosite-1 inhibitors. Therefore, the combined blockade of exosite-1 and PAR4 may offer a potential strategy for improving the balance of benefits and risks of antithrombotic therapy.

Keywords

Platelet activation - thrombin - exosite - protease-activated receptors

Full Text

References

References
1 Crawley JT, Zanardelli S, Chion CK. et al. The central role of thrombin in hemostasis. J Thromb Haemost 2007; 05: S95-S101.
2 Martorell L, Martínez-González J, Rodríguez C. et al. Thrombin and protease-activated receptors (PARs) in atherothrombosis. Thromb Haemost 2008; 99: 305-315.
3 Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 2005; 03: 1800-1814.
4 Leger AJ, Covic L, Kuliopulos A. Protease-activated receptors in cardiovascular diseases. Circulation 2006; 114: 1070-1077.
5 Alban S. Pharmacological strategies for inhibition of thrombin activity. Curr Pharm Des 2008; 14: 1152-1175.
6 Steffel J, Lüscher TF. Novel anticoagulants in clinical development: focus on factor Xa and direct thrombin inhibitors. J Cardiovasc Med 2009; 10: 616-623.
7 Di Cera E. Thrombin interactions. Chest 2003; 124: 11S-17S.
8 Krishnaswamy S. Exosite-driven substrate specificity and function in coagulation. J Thromb Haemost 2005; 03: 54-67.
9 Bock PE, Panizzi P, Verhamme IM. Exosites in the substrate specificity of blood coagulation reactions. J Thromb Haemost 2007; 05: S81-S94.
10 Rose T, Di Cera E. Three-dimensional modeling of thrombin-fibrinogen interaction. J Biol Chem 2002; 277: 18875-18880.
11 Hirsh J, O’Donnell M, Eikelboom JW. Beyond unfractionated heparin and warfarin: current and future advances. Circulation 2007; 116: 552-560.
12 Harenberg J. Development of new anticoagulants: present and future. Semin Thromb Hemost 2008; 34: 779-793.
13 Warkentin TE, Greinacher A, Koster A. Bivalirudin. Thromb Haemost 2008; 99: 830-839.
14 Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337: 688-698.
15 Schwienhorst A. Direct thrombin inhibitors – a survey of recent developments. Cell Mol Life Sci 2006; 63: 2773-2791.
16 Naski MC, Fenton 2nd JW, Maraganore JM. et al. The COOH-terminal domain of hirudin. An exosite-directed competitive inhibitor of the action of alpha-thrombin on fibrinogen. J Biol Chem 1990; 265: 13484-13489.
17 Claeson G. Synthetic peptides and peptidomimetics as substrates and inhibitors of thrombin and other proteases in the blood coagulation system. Blood Coagul Fibrinolysis 1994; 05: 411-436.
18 Nimjee SM, Rusconi CP, Harrington RA. et al. The potential of aptamers as anticoagulants. Trends Cardiovasc Med 2005; 15: 41-45.
19 Schumacher WA, Steinbacher TE, Heran CL. et al. Comparison of thrombin active site and exosite inhibitors and heparin in experimental models of arterial and venous thrombosis and bleeding. J Pharmacol Exp Ther 1993; 267: 1237-1242.
20 Muramatsu R, Sasaki M, Watanabe N. et al. Antithrombotic effects of NE-6505, a novel anion-binding exosite inhibitor. Thromb Res 1997; 86: 453-460.
21 Kelly AB, Maraganore JM, Bourdon P. et al. Antithrombotic effects of synthetic peptides targeting various functional domains of thrombin. Proc Natl Acad Sci USA 1992; 89: 6040-6044.
22 Ayala YM, Cantwell AM, Rose T. et al. Molecular mapping of thrombin-receptor interactions. Proteins 2001; 45: 107-116.
23 Nakanishi-Matsui M, Zheng YW, Sulciner DJ. et al. PAR3 is a cofactor for PAR4 activation by thrombin. Nature 2000; 404: 609-613.
24 Jacques SL, Kuliopulos A. Protease-activated receptor-4 uses dual prolines and an anionic retention motif for thrombin recognition and cleavage. Biochem J 2003; 376: 733-740.
25 Jakubowski JA, Maraganore JM. Inhibition of coagulation and thrombin-induced platelet activities by a synthetic dodecapeptide modeled on the carboxy-terminus of hirudin. Blood 1990; 75: 399-406.
26 Bock LC, Griffin LC, Latham JA. et al. Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature 1992; 355: 564-566.
27 Wu CC, Wang TW, Wang WY. et al. 2-(2-Br-phenyl)-8-methoxy- benzoxazinone (HPW-RX2), a direct thrombin inhibitor with a suppressive effect on thromboxane formation in platelets. Eur J Pharmacol 2005; 527: 37-43.
28 Wang WY, Wu YC, Wu CC. Prevention of platelet glycoprotein IIb/IIIa activation by 3,4-methylenedioxy-beta-nitrostyrene, a novel tyrosine kinase inhibitor. Mol Pharmacol 2006; 70: 1380-1389.
29 Wu CC, Teng CM. Comparison of the effects of PAR1 antagonists, PAR4 antagonists, and their combinations on thrombin-induced human platelet activation. Eur J Pharmacol 2006; 546: 142-147.
30 Dougan H, Weitz JI, Stafford AR. et al. Evaluation of DNA aptamers directed to thrombin as potential thrombus imaging agents. Nucl Med Biol 2003; 30: 61-72.
31 Ahn HS, Foster C, Boykow G. et al. Inhibition of cellular action of thrombin by N3-cyclopropyl-7-[[4-(1-methylethyl)phenyl]methyl]-7H-pyrrolo[3, 2-f]quinazoline-1,3-diamine (SCH 79797), a nonpeptide thrombin receptor antagonist. Biochem Pharmacol 2000; 60: 1425-1434.
32 Shebuski RJ, Kilgore KS. Role of inflammatory mediators in thrombogenesis. J Pharmacol Exp Ther 2002; 300: 729-735.
33 Andre P. P-selectin in haemostasis. Br J Haematol 2004; 126: 298-306.
34 Burger PC, Wagner DD. Platelet P-selectin facilitates atherosclerotic lesion development. Blood 2003; 101: 2661-2666.
35 Kahn ML, Nakanishi-Matsui M, Shapiro MJ. et al. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest 1999; 103: 879-887.
36 Leger AJ, Jacques SL, Badar J, Kaneider NC, Derian CK, Andrade-Gordon P, Covic L, Kuliopulos A. Blocking the protease-activated receptor 1–4 heterodimer in platelet-mediated thrombosis. Circulation 2006; 113: 1244-1254.
37 Ofosu FA, Dewar L, Craven SJ. et al. Coordinate activation of human platelet pro-tease-activated receptor-1 and –4 in response to subnanomolar alpha-thrombin. J Biol Chem 2008; 283: 26886-26893.
38 Anderluh M, Dolenc MS. Thrombin receptor antagonists; recent advances in PAR-1 antagonist development. Curr Med Chem 2002; 09: 1229-1250.
39 Wu CC, Hwang TL, Liao CH. et al. Selective inhibition of protease-activated receptor 4-dependent platelet activation by YD-3. Thromb Haemost 2002; 87: 1026-1033.
40 Wu CC, Hwang TL, Liao CH. et al. The role of PAR4 in thrombin-induced thromboxane production in human platelets. Thromb Haemost 2003; 90: 299-308.
41 Witting JI, Bourdon P, Brezniak DV. et al. Thrombin-specific inhibition by and slow cleavage of hirulog-1. Biochem J 1992; 283: 737-743.
42 Bouton MC, Jandrot-Perrus M, Moog S. et al. Thrombin interaction with a recombinant N-terminal extracellular domain of the thrombin receptor in an acellular system. Biochem J 1995; 305: 635-641.
43 Xu WF, Andersen H, Whitmore TE. et al. Cloning and characterization of human protease-activated receptor 4. Proc Natl Acad Sci USA 1998; 95: 6642-6646.
44 Soslau G, Class R, Morgan DA. et al. Unique pathway of thrombin-induced platelet aggregation mediated by glycoprotein Ib. J Biol Chem 2001; 276: 21173-21183.
45 Soslau G, Goldenberg SJ, Class R. et al. Differential activation and inhibition of human platelet thrombin receptors by structurally distinct alpha-, beta- and gamma-thrombin. Platelets 2004; 15: 155-166.
46 Alexander RJ, Fenton 2nd JW, Detwiler TC. Thrombin-platelet interactions: an assessment of the roles of saturable and nonsaturable binding in platelet activation. Arch Biochem Biophys 1983; 222: 266-275.
47 Becker RC, Rusconi C, Sullenger B. Nucleic acid aptamers in therapeutic anticoagulation. Technology, development and clinical application. Thromb Haemost 2005; 93: 1014-1020.
48 Gopinath SC. Anti-coagulant aptamers. Thromb Res 2008; 122: 838-847.